Loading clinical trials...
Loading clinical trials...
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Conditions
Interventions
Abiraterone acetate
Dutasteride
+1 more
Locations
4
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
University of Washington Medical Center
Seattle, Washington, United States
Start Date
September 1, 2011
Primary Completion Date
January 1, 2016
Completion Date
March 15, 2017
Last Updated
March 15, 2018
NCT06926283
NCT06594926
NCT06844383
NCT07177937
NCT07004582
NCT05919264
Lead Sponsor
Mary-Ellen Taplin, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions